This biotechnology company aims to save lives through their transformative medical device.

COLUMBIA, Md., (September 23, 2024) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $250,000 Builder Fund investment in CarrTech, a life sciences company working to support patients and healthcare providers. The Builder Fund is part of TEDCO’s Social Impact Funds, an umbrella of funds designed to support underserved founders and communities.

“The purpose of CarrTech and our medical device FROG®, is saving lives by mitigating the risk of preparing ampoule-based medication,” said CarrTech’s founder and CEO Sue Carr. “My team and I are incredibly optimistic about the huge impact TEDCO’s investment could bring to the healthcare community.”

WILMINGTON, Del., September 20, 2024 – FLUMIST® has been approved in the US as the only self-administered influenza vaccine. FLUMIST, a needle-free nasal spray, was approved to be self-administered by adults up to 49 years of age or administered by a parent/caregiver to individuals 2-17 years of age.1

The approval by the US Food and Drug Administration (FDA) was based on a comprehensive submission, which included results from a usability study demonstrating that individuals over 18 years of age could self-administer or administer FLUMIST to eligible individuals 2-49 years of age.1

What’s happening? ARPA-H is launching the Emerging Health Innovators (EHI) Initiative to increase access to government research funding for early career researchers and community health innovators to address health care gaps in the U.S.

Why it matters? Early career researchers and community health innovators, including those from minority-serving institutions and community-based organizations, will now have more opportunities to pursue bold and technically risky R&D projects, but who have been unable to take these leaps using traditional funding opportunities.

Clinicians caring for children are often left to rely on off-label devices and medications approved for adults, especially during national disasters and other emergencies. Children’s National Hospital is launching a new partnership with the federal Biomedical Advanced Research and Development Authority (BARDA) to develop much-needed solutions for this vulnerable population.

This new pediatric-focused hub will be known as the SPARK Hub—or the Hub for Special Populations Acceleration, Research and Knowledge for Innovations in Pediatrics. It will join a network of four existing BARDA hubs to develop various tools for national health emergencies, including infectious disease outbreaks or chemical, biological, radiological and nuclear attacks. The new opportunity for Children’s National positions the organization as a leader among those working to ensure clinicians and their patients have the resources they need in crises, approved for kids and ready for clinical use.

With COVID-19 still spreading and mpox emerging as a public health emergency of international concern, the National Institutes of Health (NIH) is upping preparations for future pandemics.

The Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness network (ReVAMPP) will research pathogens that currently lack effective treatments and vaccines, with the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) committing up to $100 million per year to the effort so long as funds are available, the agency announced Sept. 13.

“In the wake of the COVID-19 pandemic and ongoing outbreaks of emerging infectious diseases, the need for robust pandemic preparedness is evident,” NIAID Director Jeanne M. Marrazzo, M.D., said in the release. “The ReVAMPP network will enable researchers to fill key knowledge gaps and identify strategies to develop safe and effective medical countermeasures for targeted virus families before the need becomes critical.”

TOKYO, September 18, 2024 — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that DIGITIVA™, a non-invasive digital health solution for heart failure management, has been listed with the U.S. Food and Drug Administration (FDA). DIGITIVA is classified as a Class I Software as a Medical Device (SaMD) and is exempt from 510(k) premarket submission*. DIGITIVA is the first digital health offering from Astellas in the U.S.

DIGITIVA is designed to place patients impacted by heart failure at the center of their care, allowing them to take a more active role in managing their health while working in partnership with their care team. DIGITIVA is comprised of three components: the CORE 500™ Digital Stethoscope developed by Eko Health Inc., a smartphone app designed for heart failure patients and built on the Welldoc, Inc. platform, bolstered by educational content from the American Heart Association, and a dedicated clinical review team. The DIGITIVA clinical review team triages patient data, including previously elusive biomarkers specific to heart failure, and notifies the patient’s treating physician when certain signals are present that may indicate the patient would benefit from intervention, with the goal of impacting clinical outcomes such as acute decompensation events and re-hospitalizations.

RICHMOND, Va., Sept. 17, 2024 /PRNewswire/ -- Activation Capital proudly announces the launch of Start-the-Journey, a new BioHealth Pre-Accelerator designed to equip early-stage biotech and life science entrepreneurs with the knowledge and tools to build successful startups. Powered by Fat Robin Consulting, this innovative program supports founders in the initial phases of their entrepreneurial journey, preparing them for more advanced initiatives like Activation Capital's Frontier BioHealth, launched earlier this year to support scaling advanced-stage startups.

WASHINGTON, DC (September 17, 2024) – Today, the Biotechnology Innovation Organization (BIO) awarded Virginia Governor Glenn Youngkin with its 2024 Governor of the Year Award. 

BIO’s annual award honors governors for their leadership and commitment to strengthening biotechnology in their state. For over a decade, the award has recognized governors from across the country and both sides of the aisle.

“Investing in biotechnology is investing in Virginia’s future,” said Governor Glenn Youngkin. “As the Commonwealth’s cutting-edge research triangle and network continues to expand, my administration is determined to remain at the forefront of fostering innovation. I am incredibly humbled to receive this award, and I look forward to further solidifying Virginia’s role as a leader in the life sciences industry.”

COLUMBIA, Md., Sept. 17, 2024 /PRNewswire/ -- The Maryland Stem Cell Research Commission (MSCRC) announces the allocation of approximately $4.5 million in new grant awards to advance stem cell research and technology. These grants will drive innovative research with the potential to deliver life-saving treatments and transformative cures for patients with a variety of medical conditions.

This award has been awarded to 11 accomplished scientists from Maryland-based institutions and companies. The awardees include researchers from renowned academic institutions such as Johns Hopkins University and the University System of Maryland, as well as pioneering companies such as Therapative Inc. and Caleo Biotechnologies, Inc. Non-profit organizations, including Regenerative Orthopedics and Sports Medicine, LLC are also among the recipients. The grants will support critical research into treatments for brain diseases such as Alzheimer's and dementia, blindness, autoimmune diseases, inflammatory bowel disease and orthopedic conditions, among others.

The much-anticipated BioHealth Capital Region Week is finally upon us, promising three days packed with keynotes, competitions, and invaluable networking opportunities. Here's what attendees can look forward to each day:

Day 1 Highlights: The 10^th Annual BioHealth Capital Forum will open with two special guests—one in the morning and another in the afternoon—setting the tone for a day of high-level discussions and networking opportunities. Keynotes for the day include:

• AMGEN’s Entrance to the BioHealth Capital Region: Robert Stoffel, VP of Rare Disease, Complex Biologics, and Strategic Technology Alliances at Amgen, will discuss the company's strategic initiatives and their impact on the region.
• State of the Bio Industry: John Crowley, President and CEO of BIO, will provide an insightful look into the current landscape and future directions of the Bio industry.

Day 2 Highlights: Day two features the highly competitive Crab Trap competition with finalists Cerillo, Immobazyme, Linshom Medical, Liquet, Optosurgical, and Plakous Therapeutics. These innovative companies will pitch their groundbreaking advances to a panel of esteemed judges.

Rockville, MD—September 17^th, 2024 —The BioHealth Capital Region Forum is honored to announce that Maryland Governor Wes Moore will attend the event this morning to deliver welcoming remarks between 9:00 am – 10:00 am. As the premier gathering for the biohealth industry in Maryland and the surrounding region, the Forum celebrates the significant contributions of this sector’s vitality and innovation landscape.

Governor Moore’s presence underscores the importance of the biohealth industry to Maryland and highlights his administration’s commitment to supporting this vital sector. “We are thrilled to welcome Governor Moore to the BioHealth Capital Region Forum. His continued support plays a crucial role in our mission to advance Maryland as a top biohealth hub in the country,” said Rich Bendis, President and CEO of BioHealth Innovation, Inc.

COLUMBIA, Md. (September 16, 2024) — TEDCO, the Maryland Technology Development Corporation, is thrilled to announce the 10th Entrepreneur Expo, set to take place on Wednesday, December 4, 2024, at the Renaissance Harborplace Baltimore Hotel. This premier, award winning event caters to a diverse audience, previously comprised of entrepreneurs (65%), individuals in the economic development industry (11%), speakers and thought leaders (6%) and others (18%), making it a key gathering for Maryland's entrepreneurial community, showcasing resources and providing invaluable networking opportunities.

ROCKVILLE, Md. and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company, today announced they are entering into a strategic platform license (SPL) agreement.

Under the terms of the agreement, Kamau obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation^® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive annual licensing fees and program-related revenue.

Frederick, MD, September 13, 2024 — VaLogic Bio, a platform company of 424 Capital and a leading provider of compliance and SaaS services to the life sciences industry, proudly announces the acquisition of Facility Logix (FLGX), a renowned firm specializing in planning, developing, and project management for life sciences facilities. This acquisition aligns with VaLogic Bio’s strategic vision to enhance its capabilities and broaden its footprint in the life sciences sector.

COLLEGE PARK, Md., September 11, 2024--(BUSINESS WIRE)--IonQ (NYSE: IONQ), a leader in the quantum computing industry, and the University of Maryland (UMD), an international powerhouse in quantum research and applications, today announced an agreement to expand their partnership to provide state-of-the-art quantum computing access at the National Quantum Lab at Maryland (QLab). QLab provides UMD-affiliated students, faculty, researchers, staff and partners with an unprecedented opportunity to work closely with IonQ’s scientists and engineers as they gain experience with industry-leading trapped ion quantum computers.

QLab, a first-of-its-kind lab for quantum research and development, has supported multiple cohorts of undergraduate interns, multiple academic research projects, and multiple companies within UMD’s Quantum Startup Foundry and Mid-Atlantic Quantum Alliance. Workshops have also been held for government partners such as NASA Goddard Space Flight Center, as well as other events and tours for government and international visitors.

PASADENA, Calif., Sept. 10, 2024 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative mega campuses in AAA life science innovation cluster locations, today announced that Joel S. Marcus, the company's executive chairman and founder, is being honored with the inaugural Bisnow Life Sciences Icon & Influencer Award tomorrow afternoon, Wednesday, September 11, 2024. This prestigious award highlights Mr. Marcus and Alexandria's significant long-term contributions to and lasting impact on the life science real estate sector and broader life science industry. He will accept the award on his own behalf and that of Alexandria at Bisnow's International Life Sciences & Biotech Conference in Rockville, Maryland.

In a recent MedCity News article, Renée Arnold, entrepreneur-in-residence at BioHealth Innovation and the National Institutes of Health, emphasizes the critical importance of early planning for reimbursement strategies in digital health startups. She discusses the common misconception that securing a reimbursement code is the final hurdle, when in reality, startups must ensure insurers will cover their product and that the payment aligns with their pricing model. Learn more about why startups need to integrate reimbursement planning early in their journey and avoid potential setbacks post-FDA approval.

Why Digital Health Startups Should Start Thinking About Their Reimbursement Pathway Earlier

By Katie Adams on September 10, 2024 - Some of the most challenging yet most important processes for digital health startups to navigate are those related to reimbursement and coding.

Maryland-based business has the potential to reshape the ophthalmology and neurology sectors

COLUMBIA, Md., (September 10, 2024) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $200,000 Builder Fund investment in JuneBrain Inc., a biotechnology company. TEDCO’s Pre-Seed Builder Fund is part of TEDCO’s Social Impact Funds, which were created to engage and invest in economically underserved founders and communities.

“JuneBrain was originally started to creatively support patients and those who care for them,” said Dr. Samantha Scott, founder and CEO. “TEDCO’s continued investments in us have helped our goals and unique strategies come to fruition.”

The Maryland Department of Commerce has officially opened the 2025 Biotechnology Investment Incentive Tax Credit (BIITC) program. Qualified Maryland Biotechnology Companies (QMBCs) can submit Form B applications starting on August 20, 2024, while investors can submit Form A applications starting September 3, 2024. The program offers income tax credits ranging from 33% to 75% of eligible investments, depending on the QMBC's location and specific program qualifications.

Enhanced credits are available for investors in Opportunity Zones and RISE Zones, with higher tax credits based on eligibility. Registration for the investor queue opens on September 24, 2024, and applications are processed on a first-come basis, with limited funding available. Be sure to apply early through the Commerce online system to take advantage of these tax benefits. For more information, please visit the official BIITC program page.

The U.S. Economic Development Administration (EDA) is accepting applications for its FY24 $50 million Build to Scale program to support organizations that strengthen entrepreneurial ecosystems to support entrepreneurs as they build and scale technology-driven businesses—and the employees in the new, good jobs they create—to make and deliver new technology products and services. [Read Today’s Blog Post] 

Build to Scale (B2S) grants fund programs that support innovators, entrepreneurs, and startups transforming ideas into the critical, emerging technologies of the future.  

GAITHERSBURG, Md., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM).

Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) product candidate targeting B-cell maturation antigen (BCMA). Descartes-08 is designed to be administered without preconditioning chemotherapy and does not use integrating vectors.

Billions in funding from the CHIPS & Science Act, Bipartisan Infrastructure Law, Inflation Reduction Act, and American Rescue Plan–known as the Investing in America suite of bills– have begun to flow into communities.

Over the next two years, it will be essential that state and local governments, industry, higher education institutions, workforce entities, labor unions, and the media effectively track and evaluate the flow of funding and the activities those funds are catalyzing.

A new tool released by the U.S. National Science Foundation’s (NSF) Technology, Innovation, and Partnerships Directorate aims to help illuminate just that. The interactive map shows the 198 signature place-based investments, highlighting the geographic diversity and intentional layering of investments across the two agencies.

The BioHealth Capital Region is proud to announce the finalists for this year’s Crab Trap Competition, selected from a highly competitive pool of a record number of over 60 applications from within the Region and beyond. These finalists represent a diverse and innovative group of biohealth companies, each bringing forward unique solutions with the potential to significantly impact the industry. The competition will take place on September 18th at 1:45 pm at the US Pharmacopeia in Rockville, MD, as part of the BioHealth Capital Region Week.

The Crab Trap competition is designed to identify and foster the most innovative startups within the biohealth sector. It serves as a platform for emerging companies to gain exposure and interact with a network of industry leaders, investors, and potential partners. This year’s finalists were chosen based on their technological innovation, potential market impact, and the strength of their business model. The competition not only highlights cutting-edge advancements in healthcare and biotechnology but also provides a critical opportunity for startups to accelerate their journey from concept to market. As these companies prepare to present their solutions, the anticipation builds for how these innovations could reshape the future of medicine and healthcare.

RICHMOND, VA — Governor Glenn Youngkin today announced that Canon Virginia, Inc., a leading global manufacturer of consumer and office products, will expand its manufacturing facility in the City of Newport News. The expansion will support Canon’s new initiative to scale a unique method of isolating natural silk protein to create a solution with applications for multiple industries. Canon Virginia will retrain 30 employees to staff the new line, which is one of the company’s first ventures outside their longstanding core business of image-related products.

ARPA-H has announced a new funding opportunity through its PRECISE-AI program, aimed at maintaining the accuracy and reliability of AI-enabled medical tools over time. As AI continues to transform healthcare, tools can degrade due to evolving data, patient populations, or operations. PRECISE-AI seeks to develop solutions that automatically detect and address these issues, ensuring safer, more effective care. With over 950 AI-enabled medical devices now authorized by the FDA, this initiative is critical to future healthcare innovations.

For more information, visit the PRECISE-AI program page.

Emmes, part of Emmes Group, today announced they will provide a Clinical Coordinating Center for the NIH's National Institute on Drug Abuse Clinical Trials

ROCKVILLE, Md., Sept. 4, 2024 /PRNewswire/ -- Emmes, part of Emmes Group, a leading specialty tech-enabled global contract research organization (CRO), has been selected by the National Institutes of Health's (NIH) NIDA [National Institute of Drug Abuse] to support their Clinical Trials Network (CTN) for a multi-task, IDIQ contract.

The International Life Sciences Real Estate Conference, taking place on September 11-12, 2024, at the Bethesda North Marriott Hotel & Conference Center in Rockville, MD, is an event for professionals at the crossroads of biotech and commercial real estate. This conference will explore the latest trends, innovations, and strategies shaping the life sciences sector. Attendees will gain insights from top executives, developers, investors, and government officials on how to build thriving biotech ecosystems, navigate market conditions, and leverage AI and sustainability for future growth. Speakers include Maryland Governor Wes Moore and AstraZeneca's Cory Matthews.

ROCKVILLE, Md., Sept. 3, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive results from the Phase I/II/III CAMPSIITE^® trial of RGX-121 for the treatment of patients with Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome. The results were presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024.

The totality of evidence from the CAMPSIITE trial continues to support RGX-121 as the potential first gene therapy and one-time treatment for MPS II. In the United States, RGX-121 is also on track to be the first treatment that addresses the neurocognitive decline associated with MPS II, with the potential to be the first-line treatment for patients with neuronopathic disease. 

GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that the first patient has been dosed in its first-in-human Phase 1 trial of Descartes-15, the Company’s next-generation autologous anti-B cell maturation antigen (BCMA) mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T).

As we approach the exciting BioHealth Capital Region Week, slated to kick off in just two weeks, there's still time to secure your spot at two of the region’s most anticipated events. The BioHealth Capital Region Forum and the Investment Conference are set to bring together industry leaders, innovators, and entrepreneurs from across the biohealth spectrum.

Growing Participation: With over 500 attendees already registered for the Forum and nearly 150 organizations signed up for the Investment Conference, the buzz is building. These events offer unparalleled opportunities for networking, learning, and collaboration, attracting a diverse group of participants from the biohealth industry.

Crab Trap Competition: While applications for the Crab Trap competition have closed, we encourage everyone to register for the Forum to witness this innovation showcase. The finalists, who will be announced soon, will pitch their groundbreaking solutions to a panel of expert judges in a bid to win prizes and gain exposure.

Why You Should Attend:

• Networking Opportunities: Connect with key industry players, potential investors, and partners.
• Educational Insights: Gain valuable insights from leading experts during panels and keynotes addressing the latest trends and challenges in the biohealth sector.
• Investment Prospects: For startups and investors, the Investment Conference offers a platform to explore potential funding and growth opportunities.
• Inspiring Content: Witness firsthand the innovative prowess of emerging companies during the Crab Trap competition.

Acknowledging Our Supporters: We extend our deepest thanks to our sponsors, whose generous support has made it possible for all attendees to participate free of charge. Additionally, our planning committees have been instrumental in crafting another year of engaging and insightful events, ensuring that the BioHealth Capital Region continues to thrive as a leading hub for biohealth innovation.

Don't Miss Out: There's still time to be part of these dynamic events. Register now to join hundreds of professionals at the forefront of the biohealth industry. Whether you're seeking knowledge, connections, or opportunities to advance your business, the BioHealth Capital Region Week is the place to be.

We look forward to welcoming you to an enriching experience that promises to elevate your understanding and engagement within the biohealth sector.

In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., sits down with Peter Ronco, Chief Executive Officer of Emmes, a global full-service Clinical Research Organization (CRO). Peter discusses his transition from leading roles at Janssen R&D and Bristol Myers Squibb to guiding Emmes' strategic direction and operations.

Peter introduces Emmes, its growth as a full-service CRO, and the recent partnership with New Mountain Capital that has accelerated global acquisitions and diversified services. He also discusses the formation of the Emmes Group, which includes Veridix AI, and the latest partnership with Mimansa AI, highlighting the impact of AI in clinical research.

Listen now via your favorite podcasting platforms:

Apple:https://apple.co/2QwoEIl
Spotify: https://spoti.fi/4dJCNf6
Amazon Music: https://amzn.to/3Zfhzl7
TuneIn: https://bit.ly/3Xbi3Gf

The conversation also covers the strategic importance of Rockville, Maryland, as Emmes' headquarters and why Montgomery County is an ideal location. Peter wraps up by outlining Emmes' future growth plans.

GAITHERSBURG, Md., Aug. 30, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for active immunization to prevent COVID-19 in individuals aged 12 and older. Novavax's vaccine is included in the recommendations issued by the U.S. Centers for Disease Control and Prevention (CDC) on June 27, 2024.

RICHMOND, Va., Aug. 28, 2024 /PRNewswire/ -- Activation Capital, an innovation ecosystem development organization, has announced the selection of 10 fast-growing startups from across the country for the inaugural Frontier BioHealth program, which commenced with an in-person gathering on August 8-9, 2024. Each company will benefit from highly specialized training, targeted mentorship, and extensive relationship-building opportunities to accelerate its growth in the life sciences and healthtech sectors.

Frontier BioHealth by Activation Capital is an educational and support program designed to provide highly specialized training, targeted mentorship, and relationship building to help scale pharmaceutical, biotech, medical device, and health-focused consumer products companies. As an independent nonprofit corporation operating on behalf of the Virginia Research Biotechnology Partnership Authority, Activation Capital is committed to advancing life sciences and other cutting-edge technologies through scientific research, commercialization, and ecosystem development.

ARLINGTON, Va., Aug. 28, 2024 /PRNewswire/ -- OxiWear, a pioneering company in wearable health technology, is proud to announce that it has received clearance from the U.S. Food and Drug Administration (FDA) for its cutting-edge oxygen monitoring device. This certification marks a significant milestone in OxiWear's mission to revolutionize patient care and enhance the quality of life for individuals with chronic diseases.

OxiWear is a cutting-edge ear pulse oximeter designed for continuous, real-time measurement of blood oxygen saturation (SpO₂) and pulse rate. This device provides unmatched accuracy and convenience while still and during motion, across all skin types, within clinical and home environments. Unlike traditional methods, OxiWear ensures that patients and healthcare providers have constant access to important oxygen saturation data. The continuous data collection capability is vital for the early detection of hypoxemia (low oxygen levels), offering prompt haptic and emergency messaging alerts that can potentially save lives.

Rural Maryland-based biotechnology business seeks to develop new methods for image-based tissue diagnostics and assays

COLUMBIA, Md., (August 27, 2024) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $25,000 Pre-Seed Rural Business Innovation Initiative (RBII) investment in NEOPATHOLOGY CORP. TEDCO’s RBII was designed to enhance technology commercialization and provide technical and business assistance to small and early-stage companies based in rural Maryland.

“Our proprietary approach standardizes the tissue diagnostic process using contemporary spatial biology-enabling platforms,” said Paul Aiyetan, founder, CEO and director of NEOPATHOLOGY CORP. “Through this process, we are hoping to reduce diagnostic errors, improve diagnostic accuracy and expedite the time to treatment initiation. Thanks to TEDCO’s investment, we can continue progressing towards our goals.”